Lonza Announces Executive Committee Changes
- Marc Funk has been appointed COO of the Pharma&Biotech segment as Stephan Kutzer has decided to leave Lonza.
Basel, Switzerland, 28 April 2014 – Lonza Group Ltd announced today changes in the composition of Lonza’s Executive Committee (EC) to ensure continuity and focused delivery of the Pharma&Biotech growth strategy.
As of 1 July 2014, Marc Funk will take on the full leadership role for the Pharma&Biotech segment. Stephan Kutzer has announced that he will be leaving Lonza, but he will ensure that the handover is completed by that date. For a period of time, he will continue to complete additional transitional activities as required.
“Marc has been the Group’s Chief Legal Officer and Board Secretary since 2009 and a member of the EC since 2012,” said Richard Ridinger, CEO of Lonza. “He has already successfully managed operational and commercial projects in the Pharma&Biotech network and has been responsible for Global Quality in Pharma&Biotech for more than a year. Also he has broad experience in this field as he was formerly co-founder of a biotech research company and has had a strong commercial focus in other parts of his career. I am confident he’ll be able to steer that segment through this critical growth phase and into the future.”
During the transition period, Marc Funk will continue as the Group’s Chief Legal Officer and Board Secretary until his successor for this role is announced in due course.